A growing market for pharmaceuticals in Iran
Iran’s spending on pharmaceuticals is forecast to reach $4.14 billion by 2019, according to market insight firm Frost & Sullivan.
The country is ranked 15th among Middle East and Africa (MEA) countries in terms of long-term investment potential. With a population of 75 million – more than 50% under the age of 35 – and wealth coming in from its oil and gas reservoirs, Iran’s Gross Domestic Product (GDP) is expected to grow at an average of 2.4% over the next 10 years.
The report says the young population, coupled with the health care industry’s room for improvement, promise growth in the private sector and investments in the pharmaceutical, health care facilities and medical devices market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze